Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized, double-blind, placebo-controlled study of venglustat in Fabry disease
2021-002350-90Phase 3Active
- Sponsor
- Sanofi
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fabry disease (FD) comparing Venglustat with Placebo (2 arms). Primary endpoint: Percent change from baseline at 6 months in most bothersome Fabry pain symptom. Started Oct 2021; status: active.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2021-002350-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002350-90.